Stichodactyla toxin (ShK) is a 35-residue basic peptide from the sea anemone Stichodactyla helianthus that blocks a number of potassium channels.
History
Stichodactyla helianthus is a species of sea anemone (Phylum: Cnidaria) belonging to the family Stichodactylidae. Helianthuscomes from the Greek words Helios meaning sun, and anthos meaning flower, which corresponds to S. helianthus common name "sun anemone". It is sessile and uses potent neurotoxins for defense against its primary predator, the spiny lobster. [1] The venom contains, among other components, numerous ion channel-blocking peptides. Figure 1 shows key milestones in the discovery of ShK and its development into a therapeutic for autoimmune diseases. In 1995, a group led by Olga Castaneda and Evert Karlsson isolated ShK, a potassium channel-blocking 35-residue peptide from S. helianthus. [2] The same year, William Kem and his collaborator Michael Pennington synthesized and folded ShK, and showed it blocked neuronal and lymphocyte voltage-dependent potassium channels. [3] In 1996, Ray Norton determined the three-dimensional structure of ShK. [4] In 2005-2006, George Chandy, Christine Beeton and Michael Pennington developed ShK-170 and ShK-186, selective blockers of Kv1.3.
[5] [6] ShK-186, now called Dalazatide, was advanced to human trials in 2015-2017 by Shawn Iadonato and Eric Tarcha, as the first-in-man Kv1.3 blocker for autoimmune disease. [7] Structure ShK is cross-linked by three disulfide bridges: Cys3-Cys35, Cys12-Cys28, and Cys17-Cys32 (Figure 2) . The solution structure of ShK reveals two short α-helices comprising residues 14-19 and 21-24 ; the N-terminal eight residues adopt an extended conformation, followed by a pair of interlocking turns that resemble a 310 helix; the C-terminal Cys35 residue forms a nearly headto-tail cyclic structure through a disulfide bond with Cys3. [4] [8] [9] [10] [11] [12] Figure 3 shows the three-dimensional structure of ShK with key residues, in addition to the structures of related peptides: MMP-23's ShK domain, BmK1 (from the filarial worm), and ShK-192 (an analogue of , and the homology model of ShK-EWSS.
Phylogenetic relationships of ShK and ShK domains
The SMART database at the EMBL, as of May 2018, [13] lists 3345 protein domains with structural resemblance to ShK in 1797 proteins (1 to 8 domains/protein), many in the worm Caenorhabditis elegans and venomous snakes. [14] [15] [16] [17] [18] The majority of these domains are in metallopeptidases, whereas others are in prolyl 4-hydroxylases, tyrosinases, peroxidases, oxidoreductases, or proteins containing epidermal growth factor-like domains, thrombospondin-type repeats, or trypsin-like serine protease domains. [14] [15] [16] [17] [18] The only human proteins containing ShK-like domains are MMP-23 (matrix metalloprotease 23) (Figure 3 ) and MFAP-2 (microfibril-associated glycoprotein 2).
Figure 1 | A development timeline
Discovery of ion channel blocking peptides in sea anemones [8, 9] Synthesis and folding of ShK peptide [3] Isolation of ShK peptide from Stichodactyla helianthus [2] 3D solution structure of ShK [4] ShK shown to block K v 1.3 potassium channel in human T lymphocytes at pM concentrations [10] Binding surface of ShK on neuronal K v channels determined [34] Ionization and solution properties of ShK determined; importance of Asp 5 -Lys 30 interaction [13] ShK docked in K v 1. characterized [21] Conserved lysine-aromatic dyad shown to be conserved in sea anemone and scorpion K + channel-blocking peptides [11] ShK used to demonstrate structural conservation of K v 1.3 and K Ca 3.1 external vestibules [36] Role of disulfide bonds for K v 1.3 channel-blocking activity of ShK determined [14] Role of helical capping ST-motif class 4A for stabilizing first alpha helix in ShK determined [35] ShK and ShK-Dap 22 treat disease in rat model of multiple sclerosis [76] Mutation of pore-occluding Lys 22 in ShK alters binding in K v 1.3's external vestibule [35] Type III peptidomimetics of ShK developed with micromolar potency [15] ShK-F6CA, fluorophore-tagged ShK analog with selectivity for K v 1.3 over K v 1.1 developed and used to detect K v 1.3 on T cells by flow cytometry [40] ShK-Dap 22 less potent than ShK; less selective in equilibrium binding assays than patch clamp assays; high potency for Kv1.1-Kv1.2 heteromultimers [38] ShK-170 [ShK-L5] developed as specific inhibitor of K v 1.3 [5] ShK-186 [SL5] developed as specific inhibitor of K v 1.3; ShK-186 treats pristane-induced arthritis in rats and suppresses delayed type hypersensitivity response [6] ShK-186 paralyzes and prevents activation of effector memory T cells in a DTH response; ShK-186 treats chronic relapsing-remitting EAE in a rat model of MS [68] Durable pharmacological activity of ShK-186 in rats and non-human primates [41, 42] Recombinant production of ShK in E. coli [16] ; ShK-Lys-amide specific K v 1.3 blocker developed [23] ShK-like domain in human MMP23 characterized and shown to block K v 1.3 [27] [28] [29] [30] [31] ShK treats disease in psoriasiform SCID mouse model [92] ShK-domain in C elegans protein mab-7 required for sensory ray morphogenesis [77] Native chemical ligation of ShK and X-ray structure determined [17] ShK-186 ameliorates brain injury following therapeutic brain radiation [98] ShK-like proteins and domains in parasitic worms structure determination; blockade of K v 1.3; suppression of effector memory T cells [19] PEGylated ShK-Lys 16 extensively characterized; effective in rat model of multiple sclerosis [24] ShK-EWSS developed as selective K v 1.3 blocker [25] ; Phage display using ShK scaffold uncovers selective inhibitor of KcsA channel [20] ShK-223 modulates microglial function [73] First-in-man trial of ShK-186/Dalazatide; efficacy demonstrated in placebo-controlled phase 1B trial in patients with plaque psoriasis [7] ShK analogues fused to C-termini of IgG1-Fc retain pM potency; suppress DTH; exhibit prolonged circulating half-life [48] ShK-192, stabilized analogue of ShK-186; developed and characterized [22] ShK-186 treats obesity in mouse model by activating brown fat; [18] ShK infusion into central medial nucleus thalamic neurons awakens mice from anesthesia [ Figure 4 shows the sequence similarity tree of these peptides; the tree was generated by NCBI's Constraint-based Multiple Alignment Tool (COBALT).
Channel targets
The ShK peptide blocks potassium (K + ) ion channels Kv1.1, Kv1.3, Kv1.6, Kv3.2 and KCa3.1 with nanomolar to picomolar potency, and has no effect on the HERG (Kv11.1) cardiac potassium channel ( Table  2) . [19] [20] The neuronal Kv1.1 channel and the T lymphocyte Kv1.3 channel are most potently inhibited by ShK. [8] ShK binding configuration in K + channels ShK and its analogues are blockers of the channel pore. They bind to all four subunits in the K + channel tetramer by interacting with the shallow vestibule at the outer entrance to the channel pore ( Figure  5) . [5] 
BgmaK1
XM_001897715 Brugia malayi The first is Lys22, which protrudes into and occludes the channel's pore like a "cork in a bottle" and blocks the passage of potassium ions through the channel pore (Figures 3 and  5) . [8] [23][22] [19] The second is the neighboring Tyr23, which together with Lys22 forms a "functional dyad" required for channel block. [8] [9] [22] [23] [19] Many K + channel-blocking peptides contain such a dyad of a lysine and a neighboring aromatic or aliphatic residue. [19] [20] Some K + channel-blocking peptides lack the functional dyad, but even in these peptides a lysine physically blocks the channel, regardless of the position of the lysine in the peptide sequence. [24] Additional interactions anchor ShK and its analogues in the external vestibule and contribute to potency and selectivity. For example, Arg11 and Arg29 in ShK interact with two Asp386 residues in adjacent subunits in the mouse Kv1.3 external vestibule (corresponds to Asp433 in human Kv1.3). 
ShK analogues that block the Kv1.3 channel
Several ShK analogues have been generated to enhance specificity for the Kv1.3 channel over the neuronal Kv1.1 channel and other closely related channels ( Table 2 ).
ShK-Dap

22
: This was the first analogue that showed some degree of specificity for Kv1.3. The pore-occluding lysine 22 of ShK is replaced by diaminopropionic acid (Dap) in ShK-Dap 22 . [8] [22] [25] Dap is a non-natural lysine analogue with a shorter side chain length (2.5 Å from Cα) than lysine (6.3 Å). [26] Dap 22 interacts with residues further out in the external vestibule in contrast to lysine 22 , which interacts with the channel's selectivity filter. [22] As a consequence, the orientations of ShK and ShK-Dap 22 in the external vestibule are significantly different. [22] ShK-Dap 22 exhibits >20-fold selectivity for Kv1.3 over closely related channels in whole-cell patch clamp experiments, [8] but in equilibrium binding assays it binds Kv1.1-Kv1.2 heterotetramers with almost the same potency as ShK, which is not predicted from the study of homotetrameric Kv1.1 or Kv1.2 channels. [25] ShK-F6CA: Attaching a fluorescein to the N-terminus of the peptide via a hydrophilic AEEA linker (2-aminoethoxy-2-ethoxy acetic acid; mini-PEG) resulted in a peptide, ShK-F6CA (fluorescein-6-carboxyl), with 100-fold specificity for Kv1.3 over Kv1.1 and related channels. [27] Attachment of a tetramethyl-rhodamine or a biotin via the AEEA linker to ShK's N-terminus did not increase specificity for Kv1.3 over Kv1.1. [27] The enhanced specificity of ShK-F6CA might be explained by differences in charge: F6CA is negatively charged; tetramethylrhodamine is positively charged; and biotin is neutral. [27] Subsequent studies with other analogues suggest that the negatively charged F6CA likely interacts with residues on the turret of the Kv1.3 channel as shown for ShK-192 and ShK-EWSS ( Figure 5 ). [9] [12] ShK-170, ShK-186, ShK-192 and ShK-EWSS: Based on ShK-F6CA additional analogues were made. Attaching a L-phosphotyrosine to the N-terminus of ShK via an AEEA linker resulted in a peptide, ShK-170, with 100-1000-fold specificity for Kv1.3 over related channels. ShK-186 [a.k.a. SL5; a.k.a. Dalazatide] is identical to ShK-170 except the C-terminal carboxyl is replaced by an amide. ShK-186 blocks Kv1.3 with an IC50 of 69 pM and exhibits the same specificity for Kv1.3 over closely related channels as ShK-170 ( Table 2) . [19] The L-phosphotyrosine of ShK-170 and ShK-186 rapidly gets dephosphorylated in vivo generating an analogue, ShK-198, with reduced specificity for Kv1.3 ( Table 2) . [5] [28] [29] To overcome this problem, ShK-192 and ShK-EWSS were developed. In ShK-192, the N-terminal L-phosphotyrosine is replaced by a non-hydrolyzable paraphosphonophenylalanine (Ppa), and Met21 is replaced by the non-natural amino acid norleucine to avoid methionine oxidation (Figure 3, Table 2 ).
[9] [29] In ShK-EWSS, the AEEA linker and L-phosphotyrosine are replaced by the residues glutamic acid (E), tryptophan (W) and two serines (S) (Figures 3 and 5, Table 2 ). [12] Both ShK-192 and ShK-EWSS are highly specific for Kv1.3 over related channels. ShK-K18A: Docking and molecular dynamics simulations on Kv1.3 and Kv1.1 followed by umbrella sampling simulations, paved the way to the selective Kv1.3 inhibitor ShK-K18A. [30] ShK-related peptides in parasitic worms: AcK1, a 51-residue peptide from hookworms Ancylostoma caninum and Ancylostoma ceylanicum, and BmK1, the C-terminal domain of a metalloprotease from filarial worm Brugia malayi, adopt helical structures closely resembling ShK. [31] AcK1 and BmK1 block Kv1.3 channels at nanomolar-micromolar concentrations, and they suppress rat effector memory T cells without affecting naïve and central memory T cell subsets. [31] Further, they suppress IFN-g production by human T cells and they inhibit the delayed type hypersensitivity response caused by skin-homing effector memory T cells. [31] Teladorsagia circumcincta is an economically-important parasite that infects sheep and goats. TcK6, a 90-residue protein with a C-terminal ShK-related domain, is upregulated during the mucosal dwelling larval stage of this parasite. [32] TcK6 causes modest suppression of thapsigargin-triggered IFN-g production by sheep T cells, suggesting that the parasite use this protein for immune evasion by modulating mucosal T cells. [32] Extending circulating half-life of ShK peptides Due to their low molecular mass, ShK and its analogues are prone to rapid renal elimination. In rats, the half-life is ~6 min for ShK-186 and ~11 min for ShK-198, with a clearance rate of ~950 ml/kg·min. [28] In monkeys, the half-life is ~12 min for ShK-186 and ~46 min for ShK-198, with a clearance rate of ~80 ml/kg·min. [28] PEGylation of ShK: Conjugation of polyethylene glycol (PEG) to ShK[Q16K], an ShK analogue, increased its molecular mass and thereby reduced renal clearance and extended plasma half-life to 15 h in mice and 64 h in cynomolgus monkeys. [11] PEGylation can also decrease immunogenicity and protect a peptide from proteolysis and non-specific adsorption to inert surfaces. PEGylated ShK[Q16K] prevented adoptive-transfer experimental autoimmune encephalomyelitis in rats, a model for multiple sclerosis. [11] Conjugation of ShK to larger proteins: The circulating half-life of peptides can be prolonged by coupling them to larger proteins or protein domains. [19] [33] [34] By screening a combinatorial ShK peptide library, novel analogues were identified, which when fused to the Ctermini of IgG1-Fc retained picomolar potency, effectively suppressed in vivo delayed type hypersensitivity and exhibited a prolonged circulating half-life. [35] Prolonged effects despite rapid plasma clearance: SPECT/CT imaging studies with a 111 In-DOTAconjugate of ShK-186 in rats and squirrel monkeys revealed a slow release from the injection site and blood levels above the channel blocking dose for 2 and 7 days, respectively. [28] Studies on human peripheral blood T cells showed that a brief exposure to ShK-186 was sufficient to suppress cytokine responses. [28] These findings suggest that ShK-186, despite its short circulating half-life, may have a prolonged therapeutic effect. In rats, the peptide is effective in treating disease in animal models of autoimmune diseases when administered once a day to once in 3 days. [28] In humans, subcutaneous injections twice a week are sufficient to ameliorate disease in patients with plaque psoriasis. [7] 
Peptide delivery
The low molecular mass of ShK and its analogues, combined with their high isoelectric points, makes it unlikely that these peptides will be absorbed from the stomach or intestine following oral administration. Sub-lingual delivery is a possibility. A fluorescent ShK analogue was absorbed into the blood stream at pharmacological concentrations following sublingual administration with a mucoadhesive chitosan-based gel, with or without the penetration enhancer cetrimide. [36] Delivery of the peptide as an aerosol through the lung, or across the skin, or as eye drops are also possibilities. [ 
37][38][39]
Modulation of T cell function
During T cell-activation, calcium enters lymphocytes through store-operated CRAC channels (calcium release activated channel) formed as a complex of Orai and Stim proteins. [40] [41] The rise in intracellular calcium initiates a signaling cascade culminating in cytokine production and proliferation. [40] [41] The Kv1.3 K + channel and the calcium-activated KCa3.1 K + channel in T cells promote calcium entry into the cytoplasm through CRAC by providing a counterbalancing cation efflux. [ (Figure 6) . [ Of special interest are the large number of ShK analogues developed at Amgen that suppressed interleukin-2 and interferon gamma production by T cells. [11] This inhibitory effect of Kv1.3 blockers is partial and stimulation strength dependent, with reduced inhibitory efficacy on T cells under strengthened anti-CD3/CD28 stimulation. [50] Chronically-activated CD28 null effector memory T cells are implicated in autoimmune diseases (e.g. lupus, Crohn's disease, rheumatoid arthritis, multiple sclerosis). [ 
51][52][53][54]
Blockade of Kv1.3 channels in these chronically-activated T cells suppresses calcium signaling, cytokine production (interferon gamma, interleukin-2, interleukin 17), and cell proliferation. [6] Effector memory T cells that are CD28
+ are refractory to suppression by Kv1.3 blockers when they are costimulated by anti-CD3 and anti-CD28 antibodies, but are sensitive to suppression when stimulated by anti-CD3 antibodies alone. [48] In vivo, ShK-186 paralyzes effectormemory T cells at the site of an inflammatory delayed type hypersensitivity response and prevents these T cells from activating in the inflamed tissue. [55] In contrast, ShK-186 does not affect the homing and motility of naive and TCM cells to and within lymph nodes, most likely because these cells express the KCa3.1 channel and are therefore protected from the effect of Kv1.3 blockade. [55] ShK effects on microglia Kv1.3 plays an important role in microglial activation. [56] [57] [58] [59] ShK-223, an analogue of ShK-186, decreased lipopolysaccharide (LPS) induced focal adhesion formation by microglia, reversed LPS-induced inhibition of microglial migration, and inhibited LPSinduced upregulation of EH domain containing protein 1 (EHD1), a protein involved in microglia trafficking. [60] Increased Kv1.3 expression was reported in microglia in Alzheimer plaques. [61] Kv1.3 inhibitors may have use in the management of Alzheimer's disease, as reported in a proof-of-concept study in which a small molecule Kv1.3 blocker (PAP-1) alleviated Alzheimer's diseaselike characteristics in a mouse model of AD. [62] Efficacy of ShK analogues in animal models of human diseases
Experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis
ShK, , ShK-170 and PEGylated ShK-Q16K prevent adoptive-transfer EAE in Lewis rats, a model of multiple sclerosis.
[5] [11] Since multiple sclerosis is a relapsing-remitting disease, ShK-186 and ShK-192 were [68] and therapeutic effectiveness does not appear to be compromised by compensatory over-expression of KCa3.1 channels.
[49] [69] Pristane-induced arthritis (PIA), a model for rheumatoid arthritis ShK-186 was effective in treating PIA when administered every day or on alternate days.
[5] [6] [55] [28] A scorpion toxin inhibitor of KV1.3 was also effective in this model. [70] In both these studies, blockade of Kv1.3 alone was sufficient to ameliorate disease and simultaneous blockade of KCa3.1 was not necessary as has been suggested. [ 
49][71]
Rat models of atopic dermatitis
Most infiltrating T-cells in skin lesions from patients with moderate-to-severe atopic dermatitis (AD) express high levels of Kv1.3, suggesting that inhibitors of Kv1.3 may be effective in treating AD. [72] Ovalbumininduced delayed type hypersensitivity and oxazoloneinduced dermatitis are considered to be models of atopic dermatitis. [ while a topical formulation of ShK-198 was effective in treating oxazolone-induced dermatitis. [72] Even where compensation by KCa3.1 channels was reported to over-ride KV1.3 block, ShK administered alone suppressed delayed type hypersensitivity significantly in 2 of 3 studies, albeit modestly. [49] 
Psoriasis
Psoriasis is a severe autoimmune disease of the skin that afflicts many people worldwide. Despite the success of recent biologics in ameliorating disease, there is still a search for safe and effective drugs for psoriasis. KV1.3 inhibitors (ShK, PAP-1) have been reported to treat disease in psoriasiform (psoriasis-like) SCID (severe combined immunodeficiency) mouse model. [82] In a Phase 1b placebo-controlled clinical study in patients with plaque psoriasis, ShK-186 administered twice a week (30 or 60 mg/dose/patient) by subcutaneous injection caused improvements with a statistically significant reduction in their PASI (Psoriasis Area and Severity Index) score between baseline and day 32. [7] These patients also exhibited reduced plasma levels of multiple inflammation markers and decreased expression of T cell activation markers on peripheral blood memory T cells. [7] Diet-induced obesity and fatty liver disease Obesity and diabetes are major healthcare problems globally. There is need for safe drugs for these metabolic diseases. In a mouse model of diet-induced obesity, ShK-186 counteracted the negative effects of increased caloric intake. It reduced weight gain, adiposity, and fatty liver; decreased blood levels of cholesterol, sugar, HbA1c, insulin, and leptin; and enhanced peripheral insulin sensitivity. [83] Genetic deletion of the Kv1.3 gene has the same effect, indicating that ShK-186's effect is due to Kv1.3 blockade.
[84] [83] [85] [86] At least two mechanisms contribute to ShK-186's therapeutic benefits. The high calorie diet induced Kv1.3 expression in brown fat tissues. [83] By blocking Kv1.3, ShK-186 doubled glucose uptake and increased β-oxidation of fatty acids, glycolysis, fatty acid synthesis and uncoupling protein 1 expression by brown fat. [83] As a consequence of brown fat activation, oxygen consumption and energy expenditure were augmented. [83] The obesity diet also induced Kv1.3 expression in the liver, and ShK-186 caused profound alterations in energy and lipid metabolism in the liver. ShK, its analogues or other Kv1.3 blockers may have use in controlling the negative consequences of high calorie diets.
Arousal and anesthesia
The mechanisms of general anesthesia involve multiple molecular targets and pathways that are not completely understood. [87] Sevoflurane is a common anesthetic used to induce general anesthesia during surgery. [87] Rats continually exposed to sevoflurane lose their righting reflex as an index of loss of consciousness. In these rats, microinfusion of ShK into the central medial thalamic nucleus (CMT) reversed sevoflurane-induced anesthesia in rodents. [87] ShK-treated rats righted themselves fully (restored consciousness) despite being continually exposed to sevoflurane. [87] ShKmicroinfusion into neighboring regions of the brain did not have this effect. [87] Sevoflurane enhanced potassium currents in the CMT, while ShK and ShK-186 countered this effect. [87] These studies suggest that ShKsensitive K + channels in the CMT are important for suppressing arousal during anesthesia.
Preventing brain damage following therapeutic brain radiation
Brain radiation is used to treat tumors of the head, neck, and brain, but this treatment carries a significant risk of neurologic injury. Injury is, in part, due to the activation of microglia and microglia-mediated damage of neurons. Neuroprotective therapies for radiation-induced brain injury are still limited. In a mouse model of brain radiation, ShK-170 reversed neurological deficits, and protected neurons from radiation-induced brain injury by suppressing microglia. [88] Toxicity of ShK and its analogues ShK and ShK-Dap 22 ShK peptide has a low toxicity profile in mice. ShK is effective in treating autoimmune diseases at 10 to 100 mg/kg bodyweight. It has a median paralytic dose of approximately 25 mg/kg bodyweight (250-2500 higher than the pharmacological dose). In rats the therapeutic safety index is greater than 75-fold. ShK-Dap 22 displayed a lower toxicity profile.
[8] A 1.0 mg dose did not induce any hyperactivity, seizures or mortality in rats. The median paralytic dose for ShK-Dap 22 is about 200 mg/kg bodyweight (2000-20000 higher than pharmacological dose). [8] PEGylated ShK[Q16K] showed no adverse toxicity in monkeys over a period of several months. [11] 
ShK-186/Dalazatide
ShK-186 also displays a low toxicity profile in rats. Daily administration of ShK-170 or ShK-186 (100 µg/kg/day) by subcutaneous injection over 4 weeks in rats does not induce any changes in blood counts, blood chemistry or histopathology. [5] [6] [28] By virtue of suppressing only TEM and TEMRA cells, ShK-186 did not compromise protective immune responses to influenza virus and chlamydial infection in rats, most likely because naïve and TCM cells unaffected by Kv1.3 blockade mounted effective immune responses. [55] ShK-186 is poorly immunogenic and did not elicit anti-ShK antibodies in rats repeatedly administered the peptide. [6] This is possibly because the peptide's disulfide-bonded structure hinders processing and antigen presentation by antigen-presenting cells. ShK-186 also shares sequence and structural similarity to a ShK-like domain in matrix metalloprotease 23, [14] [15] [16] [17] [18] which may cause the immune system to assume it is a normal protein in the body. ShK-186 was safe in non-human primates. In Phase 1a and 1b trials in healthy human volunteers, ShK-186 was well tolerated, no grade 3 or 4 adverse effects or laboratory abnormalities were noted, and the predicted range of drug exposures were achieved. [7] The most common adverse events were temporary mild (Grade 1) hypoesthesia and paresthesia involving the hands, feet, or perioral area. Mild muscle spasms, sensitivity of teeth, and injection site pain were also observed. [7] Functions of ShK-like domains in proteins
MMP-23 and its ShK domain
MMP-23 belongs to the family of zinc-and calcium-dependent matrix metalloproteases. It is anchored in the cell membrane by an N-terminal prodomain, and it contains three extracellular domains: catalytic metalloprotease domain, ShK domain and immunoglobulin-like cell adhesion molecule (Ig-CaM) domain. [ 4 , in decreasing potency) in the nanomolar to low micromolar range. [14] KV1.3 is required for sustaining calcium signaling during activation of human T cells. [19] [40] [47] By trapping KV1.3 in the endoplasmic reticulum via the prodomain, and by blocking the KV1.3 channel with the ShK domain, MMP-23 may serve as an immune checkpoint to reduce excessive T cell activation during an immune response. In support, increased expression of MMP-23 in melanoma cancer cells decreases tumor-infiltrating lymphocytes, and is associated with cancer recurrence and shorter periods of progression-free survival. [17] However, in melanomas, expression of MMP-23 does not correlate with Kv1.3 expression, suggesting that MMP-23's deleterious effect in melanomas may not be connected with its Kv1.3 channel-modulating function. [17] 
Mab7, a worm protein containing a ShK domain
In male Caenorhabditis elegans worms, the absence of a protein called Mab7 results in malformed sensory rays that are required for mating. [65] Introduction of Mab7 into these male worms restores normal development of normal sensory rays. [65] Introduction of Mab7 proteins lacking the ShK domain does not correct the defect of sensory rays, suggesting a role for the ShK-domain of Mab7 in sensory ray development. [65] HMP2 and PMP1, proteins containing ShK-like domains HMP2 and PMP-1 are astacin metalloproteinases from the Cnidarian Hydra vulgaris and the jellyfish Podocoryne carnea that contain ShK-like domains at their Ctermini.
[89] [18] Both these ShK-domains contain the critical pore-occluding lysine required for K + channel block. [14] HMP2 plays a critical role in foot regeneration of Hydra, [89] while PMP1 is found in the feeding organ of the jelly fish and the ShK-domain may paralyze prey after they are ingested. [18] Additional information
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